Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Press Releases
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société HUTCHMED (CHINA) LIMITED
01/20HUTCHMED CHINA : Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant..
PU
01/19HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Soli..
AQ
01/19HUTCHMED CHINA : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Ga..
PU
01/18HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastroi..
AQ
01/18TR-1 : Standard form for notification of major holdings - Form 6-K
PU
01/12HUTCHMED CHINA : Receives Break­through Therapy Designation in China for HMPL-523 for Trea..
PU
01/10HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
PU
01/09HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
AQ
01/03HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K
PU
2021HUTCHMED CHINA : Included in FTSE Russell Indexes - Form 6-K
PU
2021HUTCHMED Included in FTSE Russell Indexes
AQ
2021HUTCHMED CHINA : ​ - Form 6-K
PU
2021HUTCHMED CHINA : Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meetin..
PU
2021HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
AQ
2021HUTCHMED CHINA : Highlights Surufatinib and Toripalimab Combination Clinical Data being Pr..
PU
2021HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Present..
AQ
2021HUTCHMED CHINA : Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fru..
PU
2021HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquint..
AQ
2021HUTCHMED CHINA : Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Add..
PU
2021HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition..
AQ
2021HUTCHMED CHINA : and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO®..
PU
2021HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Comb..
AQ
2021Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now avail..
AQ
2021International companies to host live webcasts at Deutsche Bank's Depositary Receipts Vi..
AQ
2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..
PU
2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..
AQ
2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..
PU
2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..
AQ
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..
PU
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..
AQ
2021HUTCHMED CHINA : Grant of Awards under Long Term Incentive Plan - Form 6-K
PU
2021HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture (Form 6-K)
PU
2021HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture
AQ
2021HUTCHMED CHINA : Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with T..
PU
2021HUTCHMED CHINA : Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with T..
AQ
2021HUTCHMED CHINA : — Following surufatinib launch in China in January 2021; NDA accept..
PU
2021HUTCHMED CHINA : Initiates a Japan Bridging Study to Support Surufatinib Registration for ..
AQ
2021HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-..
PU
2021HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-..
AQ
2021HUTCHMED CHINA : — Follows important findings from the SAVANNAH study of this combin..
PU
2021HUTCHMED CHINA : Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-..
PU
2021HUTCHMED CHINA : Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtua..
AQ
2021HUTCHMED CHINA : Grant of Share Options under Share Option Scheme and Awards under Long Te..
PU
2021HUTCHMED CHINA : Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tisleli..
PU
2021HUTCHMED CHINA : Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tisleli..
AQ
2021HUTCHMED CHINA : Selected as Constituent of Certain Hang Seng Indexes (Form 6-K)
PU
2021HUTCHMED CHINA : Selected as Constituent of Certain Hang Seng Indexes
AQ
2021EPIZYME : and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVE..
AQ
2021HUTCHMED CHINA : Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Comm..
BU
2021HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates (Form 6-K)
PU
2021HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates
PU
2021HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates
AQ
2021HUTCHMED CHINA : — Follows multiple Phase II studies of ORPATHYS® in Asia including ..
PU
2021HUTCHMED CHINA : and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET..
AQ
2021HUTCHMED CHINA : Stabilizing Actions and End of Stabilization Period in connection with th..
AQ
2021HUTCHMED CHINA : Expands potential global reach of surufatinib, in addition to China where..
PU
2021HUTCHMED CHINA : Marketing Authorization Application for Surufatinib Submitted and Validat..
AQ
2021TR-1 : Standard form for notification of major holdings (Form 6-K)
PU
2021ASTRAZENECA : HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a..
AQ
2021HUTCHMED CHINA : Announces Full Exercise of the Over-allotment Option of the Global Offeri..
AQ
2021HUTCHMED CHINA : Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with..
PU
2021HUTCHMED CHINA : U.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatme..
PU
2021U.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced..
GL
2021HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong K..
GL
2021HUTCHMED CHINA : Blocklisting Six Monthly Return (Form 6-K)
PU
2021HUTCHMED (CHINA) : Room 2108, 22/F, Hutchison House 10 Harcourt Road, Hong Kong (Form 6-K)
PU
2021HUTCHMED CHINA : Announces Pricing of Global Offering (Form 6-K)
PU
2021HUTCHMED Announces Pricing of Global Offering
GL
2021HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET..
GL
2021HUTCHMED CHINA : The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk..
PU
2021HUTCHMED CHINA : Letter from PricewaterhouseCoopers to the Securities and Exchange Commiss..
PU
2021HUTCHMED CHINA : Launches Hong Kong Initial Public Offering (Form 6-K)
PU
2021HUTCHMED (CHINA) : Supplemental and Updated Disclosures (Form 6-K)
PU
2021HUTCHMED (CHINA) : Form 6-K)
PU
2021HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancre..
GL
1  2Next
Upcoming event on HUTCHMED (CHINA) LIMITED